Nikhil Joshi, MD
Interventional Cardiology · Sherman, TXNPI 1437253481
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,854 of the $14,380 with a category attached, or 68.5%. 43 manufacturers reported payments, led by Abbott at 24.9% of the total. Reporting peaked in 2023 at $4,733 and has fallen 56.7% since, to $2,047 in 2025.
Across 460 payments — averaging $31.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Philips North America LLC$2K
- Boston Scientific$1K
- Medtronic$1K
- Biotronik Inc.$1K
- Cardiovascular Systems Inc.$896
- plus $5K from 37 others
Across 55 payments — averaging $28,343 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.2M
- Novartis$188K
- AstraZeneca$119K
- Astrazeneca UK Limited$17K
- Boehringer Ingelheim Pharma GmbH & Co.kg$8K
- Boehringer Ingelheim International GmbH$2K
- plus $392 from 1 others
What the payments were for
- Consulting fees$7505%
- Travel & lodging$3,76226%
- Food & beverage$9,85469%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 45 | $3,575 |
| Philips North America LLC | 66 | $1,564 |
| Boston Scientific | 12 | $1,322 |
| Medtronic | 17 | $1,201 |
| Biotronik Inc. | 72 | $1,009 |
| Cardiovascular Systems Inc. | 25 | $896 |
| Pfizer | 45 | $748 |
| Merck | 35 | $593 |
| AOP Health US, LLC | 1 | $527 |
| Novartis | 24 | $420 |
| Heartflow, Inc. | 9 | $352 |
| Johnson & Johnson | 18 | $343 |
| E.r. Squibb & Sons, L.L.C. | 11 | $207 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $138 |
| Amarin Pharma, Inc. | 7 | $122 |
| Boehringer Ingelheim | 6 | $122 |
| Amgen | 9 | $115 |
| AstraZeneca | 6 | $114 |
| Atricure, Inc. | 2 | $108 |
| Novo Nordisk | 5 | $105 |
| Cleerly, Inc. | 1 | $95 |
| Cvrx, Inc. | 5 | $88 |
| Terumo Medical Corporation | 2 | $85 |
| Sanofi-aventis U.S. LLC | 4 | $82 |
| Impulse Dynamics (USA) Inc. | 3 | $72 |
| Abiomed | 1 | $38 |
| Bridgebio Pharma, Inc. | 2 | $38 |
| Imperative Care, Inc | 1 | $32 |
| Scpharmaceuticals Inc. | 2 | $28 |
| Silk Road Medical, Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Elutia, Inc. | 1 | $20 |
| Bayer | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| Cathworks, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $17 |
| Shockwave Medical, Inc | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| GSK | 1 | $15 |
| ZOLL Circulation Inc | 1 | $10 |
| Bardy Diagnostics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$1,588
- Rapiblyk$1,054
- AngioJet Ultra 5000A$986
- Accent Pacemaker$750
- HawkOne$653
- Peripheral Orbital Atherectomy System$427
- EKOSONIC$174
- Xience V coronary stent system$169
- FFRct$147
- (CX0) IGT Marketing$133
- Perclose ProGlide suture mediated closure system$115
- (6554) Peripheral Vascular Undivided$106
How this compares
$14,380 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 823 | $721,339 |
| EntrestoSacubitril/Valsartan | 318 | $269,363 |
| XareltoRivaroxaban | 320 | $256,033 |
| Repatha SureclickEvolocumab | 100 | $78,777 |
| FarxigaDapagliflozin Propanediol | 100 | $73,249 |
| MultaqDronedarone Hcl | 36 | $46,464 |
| BrilintaTicagrelor | 64 | $39,788 |
| JardianceEmpagliflozin | 55 | $32,676 |
| VerquvoVericiguat | 20 | $20,071 |
| Ranolazine ErRanolazine | 247 | $19,477 |
| VascepaIcosapent Ethyl | 28 | $16,422 |
| Metoprolol Succinate | 1,417 | $14,935 |
| Rosuvastatin Calcium | 1,051 | $11,271 |
| Ezetimibe | 561 | $8,635 |
| Atorvastatin Calcium | 850 | $6,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $748 | $721,339823 claims |
| NovartisEntresto | $420 | $269,363318 claims |
| Johnson & JohnsonXarelto | $343 | $256,033320 claims |
| AstraZenecaFarxiga, Brilinta | $114 | $113,037164 claims |
| Sanofi-aventis U.S. LLCMultaq | $82 | $46,46436 claims |
| Boehringer IngelheimJardiance | $122 | $32,67655 claims |
| MerckVerquvo | $593 | $20,07120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Sherman
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.